DaVita Inc. (DVA - Free Report) is currently one of the top-performing stocks in the MedTech space. Solid performance by the Kidney Care unit and strong fundamentals are major positives at the moment.
Shares Up
In the past year, DaVita’s shares have rallied 10% against the industry’s decline of 12.3%.
The Zacks Rank #2 (Buy) stock currently has a Growth Score of B. This reflects possibilities of outperformance over the long haul. Our research shows that stocks with a Growth Score of A or B, when combined with a Zacks Rank #1 (Strong Buy) or #2, are better picks than most.
For the current quarter, the Zacks Consensus Estimate for earnings per share is pegged at 97 cents, reflecting year-over-year growth of 5.43%.
Let’s delve deeper.
What Makes It an Attractive Pick?
Fundamental Growth Story
Since 2009, the company’s revenues have seen a CAGR of 7.5% to $10.88 billion. DaVita’s earnings have seen a CAGR of 6.8% to $3.44 over the same period.
Kidney Care in Focus
Last month, DaVita and the University of Chicago Medicine announced the successful implementation of the Transplant Waitlist Support Program. It has been created to help keep patients on the waiting list transplant-ready. This improves chances of success for patients undergoing a transplant.
Earlier this year, the company announced endorsement of the Standardised Outcomes in Nephrology (SONG) initiative. Notably, it aims to standardize outcomes in kidney care trials. Per management, SONG is currently developing core outcomes for hemodialysis (SONG-HD), transplantation (SONG-Tx), peritoneal dialysis (SONG-PD), children and adolescents (SONG-Kids), and polycystic kidney disease (SONG-PKD).
Overseas Presence
DaVita is steadily expanding in the international markets. In the past few years, the company has strengthened its position in the emerging and developing markets of Brazil, China, Colombia, Germany, India, Malaysia, Netherlands, Poland, Portugal and Saudi Arabia through strategic alliances as well as acquisitions of dialysis centers.
Key Picks
A few other top-ranked stocks in the broader medical space are Genomic Health , Stryker Corporation (SYK - Free Report) and Integer Holdings Corporation (ITGR - Free Report) .
Genomic Health has an expected earnings growth rate of 187.5%. The stock flaunts a Zacks Rank #1. You can see the complete list of today’s Zacks #1 Rank stocks here.
Stryker has a projected long-term earnings growth rate of 9.7%. The stock carries a Zacks Rank #2.
Integer Holdings a long-term expected earnings growth rate of 15%. The stock carries a Zacks Rank #2.
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Click for details >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
DaVita Inc. (DVA - Free Report) is currently one of the top-performing stocks in the MedTech space. Solid performance by the Kidney Care unit and strong fundamentals are major positives at the moment.
Shares Up
In the past year, DaVita’s shares have rallied 10% against the industry’s decline of 12.3%.
The Zacks Rank #2 (Buy) stock currently has a Growth Score of B. This reflects possibilities of outperformance over the long haul. Our research shows that stocks with a Growth Score of A or B, when combined with a Zacks Rank #1 (Strong Buy) or #2, are better picks than most.
For the current quarter, the Zacks Consensus Estimate for earnings per share is pegged at 97 cents, reflecting year-over-year growth of 5.43%.
Let’s delve deeper.
What Makes It an Attractive Pick?
Fundamental Growth Story
Since 2009, the company’s revenues have seen a CAGR of 7.5% to $10.88 billion. DaVita’s earnings have seen a CAGR of 6.8% to $3.44 over the same period.
Kidney Care in Focus
Last month, DaVita and the University of Chicago Medicine announced the successful implementation of the Transplant Waitlist Support Program. It has been created to help keep patients on the waiting list transplant-ready. This improves chances of success for patients undergoing a transplant.
Earlier this year, the company announced endorsement of the Standardised Outcomes in Nephrology (SONG) initiative. Notably, it aims to standardize outcomes in kidney care trials. Per management, SONG is currently developing core outcomes for hemodialysis (SONG-HD), transplantation (SONG-Tx), peritoneal dialysis (SONG-PD), children and adolescents (SONG-Kids), and polycystic kidney disease (SONG-PKD).
Overseas Presence
DaVita is steadily expanding in the international markets. In the past few years, the company has strengthened its position in the emerging and developing markets of Brazil, China, Colombia, Germany, India, Malaysia, Netherlands, Poland, Portugal and Saudi Arabia through strategic alliances as well as acquisitions of dialysis centers.
Key Picks
A few other top-ranked stocks in the broader medical space are Genomic Health , Stryker Corporation (SYK - Free Report) and Integer Holdings Corporation (ITGR - Free Report) .
Genomic Health has an expected earnings growth rate of 187.5%. The stock flaunts a Zacks Rank #1. You can see the complete list of today’s Zacks #1 Rank stocks here.
Stryker has a projected long-term earnings growth rate of 9.7%. The stock carries a Zacks Rank #2.
Integer Holdings a long-term expected earnings growth rate of 15%. The stock carries a Zacks Rank #2.
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Click for details >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on SYK - FREE
Get the latest research report on DVA - FREE
Get the latest research report on ITGR - FREE